Author
@BPharmCatalyst BPharmCatalyst
High-volume biotech catalyst news feed: FDA, trial readouts, M&A, financings, all tickered.
Aggregate and relay real-time clinical-stage biopharma event
trader score
·
hit rate
·
mean α
·
signals 14d
37
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved +13.5% since posting (mean over 5 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-02 | ELTX | @BPharmCatalyst | -0.35 | ELTX shares fell after $15M registered direct offering of 4.38M shares. | · | tweet ↗ |
| 2026-07-02 | ELTX | @BPharmCatalyst | -0.35 | ELTX shares fell after $15M registered direct offering of 4.38M shares. | · | tweet ↗ |
| 2026-07-02 | TNON | @BPharmCatalyst | +0.50 | TNON obtained FDA 510(k) clearance for Catamaran SI Joint Fusion System. | · | tweet ↗ |
| 2026-07-01 | CANF | @BPharmCatalyst | +0.55 | CANF Phase 2a study met primary safety endpoint and showed durable survival. | · | tweet ↗ |
| 2026-07-01 | CANF | @BPharmCatalyst | +0.55 | CANF Phase 2a Namodenoson trial met safety endpoint and showed durable survival. | · | tweet ↗ |
| 2026-06-30 | VTGN | @BPharmCatalyst | -0.75 | Phase 3 PALISADE-4 failed primary endpoint; shares closed down 70%. | · | tweet ↗ |
| 2026-06-30 | UNCY | @BPharmCatalyst | -0.45 | FDA CRL for resubmitted OLC NDA due to manufacturing issues. | · | tweet ↗ |
| 2026-06-29 | EVMN | @BPharmCatalyst | -0.60 | EVO756 missed primary endpoint in Phase 2b CSU trial and CSU development ended. | · | tweet ↗ |
| 2026-06-29 | DCOY | @BPharmCatalyst | +0.25 | Reports DCOY finalized PIPE agreement with $3.5M upfront and $17.5M potential. | · | tweet ↗ |
| 2026-06-26 | CRIS | @BPharmCatalyst | +0.15 | CRIS confirms Phase 2 sites and planned dosing/readout, plus reverse split authorization. | · | tweet ↗ |
| 2026-06-26 | PCVX | @BPharmCatalyst | +0.00 | Weekly biotech watchlist for key Phase 3 catalysts over the next six months. | · | tweet ↗ |
| 2026-06-26 | DFTX | @BPharmCatalyst | +0.00 | Weekly biotech watchlist for key Phase 3 catalysts over the next six months. | -1.7% | tweet ↗ |
| 2026-06-26 | IMCR | @BPharmCatalyst | +0.00 | Weekly biotech watchlist for key Phase 3 catalysts over the next six months. | · | tweet ↗ |
| 2026-06-26 | PHVS | @BPharmCatalyst | +0.00 | Weekly biotech watchlist for key Phase 3 catalysts over the next six months. | · | tweet ↗ |
| 2026-06-26 | IVA | @BPharmCatalyst | +0.00 | Weekly biotech watchlist for key Phase 3 catalysts over the next six months. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.